MY209101A - Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof - Google Patents

Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof

Info

Publication number
MY209101A
MY209101A MYPI2021002202A MYPI2021002202A MY209101A MY 209101 A MY209101 A MY 209101A MY PI2021002202 A MYPI2021002202 A MY PI2021002202A MY PI2021002202 A MYPI2021002202 A MY PI2021002202A MY 209101 A MY209101 A MY 209101A
Authority
MY
Malaysia
Prior art keywords
methods
solid dispersions
pharmaceutical compositions
preparation
substituted indane
Prior art date
Application number
MYPI2021002202A
Other languages
English (en)
Inventor
Christopher Lindemann
Peter J Stengel
Original Assignee
Peloton Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peloton Therapeutics Inc filed Critical Peloton Therapeutics Inc
Publication of MY209101A publication Critical patent/MY209101A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MYPI2021002202A 2018-10-30 2019-10-23 Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof MY209101A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862752685P 2018-10-30 2018-10-30
PCT/US2019/057725 WO2020092100A1 (en) 2018-10-30 2019-10-23 Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof

Publications (1)

Publication Number Publication Date
MY209101A true MY209101A (en) 2025-06-21

Family

ID=70464349

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021002202A MY209101A (en) 2018-10-30 2019-10-23 Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof

Country Status (9)

Country Link
US (2) US12358870B2 (cg-RX-API-DMAC7.html)
EP (1) EP3873443A4 (cg-RX-API-DMAC7.html)
JP (1) JP7425794B2 (cg-RX-API-DMAC7.html)
KR (1) KR102991240B1 (cg-RX-API-DMAC7.html)
CN (1) CN112955130A (cg-RX-API-DMAC7.html)
MX (1) MX418110B (cg-RX-API-DMAC7.html)
MY (1) MY209101A (cg-RX-API-DMAC7.html)
SG (1) SG11202104208RA (cg-RX-API-DMAC7.html)
WO (1) WO2020092100A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3173831A1 (en) 2020-03-19 2021-09-23 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
CN115697307A (zh) * 2020-06-19 2023-02-03 葛兰素史密斯克莱知识产权(第2 号)有限公司 包含达普司他的制剂
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
US11827614B2 (en) 2021-05-21 2023-11-28 Merck Sharp & Dohme Llc Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates
US20240327929A1 (en) * 2021-08-12 2024-10-03 Merck Sharp & Dohme Llc Dosage regimen for administration of belzutifan
US12145901B1 (en) 2021-09-17 2024-11-19 Arcus Biosciences, Inc. Process for preparing tetralin compounds
AU2023407370A1 (en) * 2022-12-22 2025-07-03 Cogent Biosciences, Inc. Bezuclastinib formulations
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
KR102824931B1 (ko) * 2023-10-17 2025-07-08 주식회사 참인티그레이션 오일 유화 공법을 이용하여 제조되는 반려동물 건강 영양제 및 이의 제조방법
AU2024393766A1 (en) 2023-12-08 2026-06-18 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4932412A (en) 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
DE60038624T2 (de) 1999-10-07 2009-06-10 Aquilar-Cordova, Carlos, Estuardo, Newton Methoden zur behandlung von festen tumoren und metastasen mit gentherapie
US7115265B1 (en) 2001-05-14 2006-10-03 Duke University Four genetic tumor markers specific for human glioblastoma
CN101827585A (zh) 2007-10-19 2010-09-08 雅培股份有限两合公司 含有n-芳基脲基化合物的固态分散体产品
US8691866B2 (en) * 2008-12-10 2014-04-08 The General Hospital Corporation HIF inhibitors and use thereof
TWI673051B (zh) 2012-09-11 2019-10-01 美商梅維森前列腺療法有限責任公司 恩雜魯它脈(enzalutamide)之調和物
CN105307636A (zh) 2013-07-19 2016-02-03 西佳技术公司 非晶形特考韦瑞制备
EP3417851B1 (en) 2013-09-09 2020-07-22 Peloton Therapeutics, Inc. Aryl ethers and uses thereof
CN113209024A (zh) 2013-12-31 2021-08-06 阿森迪亚制药有限责任公司 疏水性化合物的药物组合物
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma

Also Published As

Publication number Publication date
EP3873443A1 (en) 2021-09-08
US12358870B2 (en) 2025-07-15
WO2020092100A1 (en) 2020-05-07
MX418110B (es) 2024-11-07
KR102991240B1 (ko) 2026-07-21
SG11202104208RA (en) 2021-05-28
CA3117563A1 (en) 2020-05-07
JP7425794B2 (ja) 2024-01-31
MX2021005038A (es) 2021-06-15
EP3873443A4 (en) 2022-07-27
US20210387946A1 (en) 2021-12-16
CN112955130A (zh) 2021-06-11
KR20210091191A (ko) 2021-07-21
US20250326711A1 (en) 2025-10-23
JP2022506062A (ja) 2022-01-17

Similar Documents

Publication Publication Date Title
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX418110B (es) Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
SG11201808607SA (en) Medicine obtained by combining fxr agonist and arb
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using
CA2983481A1 (en) Janus kinase inhibitor
EP4365300A3 (en) Treatment/prevention of disease by linc complex inhibition
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
SG11202011685QA (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
EP4663247A3 (en) Formulations/compositions comprising a btk inhibitor
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
MX2020013352A (es) Tratamiento para migrañas.
MX2021007247A (es) Derivados de rapamicina.
IL276952A (en) History of 4,2-diaminoquinazolines and their medicinal uses
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
EP4467138A3 (en) Therapeutic agents for neurodegenerative diseases
WO2018187331A8 (en) Macrocyclic compound and uses thereof
EP3891122A4 (en) DECARBOXYLASE INHIBITORS FOR THE TREATMENT OF PARKINSON'S DISEASE
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
CA3035115C (en) Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof
EP4021168A4 (en) PROCESSED PLANTS AND METHODS OF MANUFACTURE AND USE THEREOF
EP4461361A3 (en) Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease
EP3970793A4 (en) MEANS OF PREVENTING, IMPROVING OR TREATMENT OF PERIODONTAL DISEASES
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.